Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.9115
+0.03664.18%
Volume:1.31M
Turnover:1.17M
Market Cap:190.18M
PE:-1.31
High:0.9482
Open:0.8562
Low:0.8150
Close:0.8749
Loading ...

Sangamo Therapeutics Inc: Collaboration and License Agreement With Pfizer Will Terminate Effective April 21, 2025

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics: Intends to Explore Options to Advance Program, Including Seeking Potential New Collaboration Partner

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics Inc: All Trial Participants Will Continue to Be Monitored as Planned During Transition Period

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics to Regain Full Rights to Hemophilia a Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

Business Wire
·
31 Dec 2024

Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
31 Dec 2024

Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Dec 2024

Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires Live
·
19 Dec 2024

Sangamo Shares Rally Premarket on License Deal With Astellas

Dow Jones
·
19 Dec 2024

Sangamo Grants Capsid License to Astellas for Neurological Disease Targets

MT Newswires Live
·
19 Dec 2024

BRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement

Reuters
·
19 Dec 2024

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

THOMSON REUTERS
·
19 Dec 2024

Sangamo Therapeutics Inc - to Receive $20 Million Upfront License Fee

THOMSON REUTERS
·
19 Dec 2024

Sangamo Therapeutics Inc - Eligible for up to $1.3 Billion in Milestone Payments

THOMSON REUTERS
·
19 Dec 2024

Truist Upgrades Sangamo Therapeutics to Buy From Hold, Reinstates Price Target at $7

MT Newswires Live
·
13 Dec 2024

Sangamo Therapeutics Shares up 3.3% After FDA Clears Application to Start Trial for Pain Treatment

THOMSON REUTERS
·
20 Nov 2024